Preclinical efficacy of prexasertib in acute lymphoblastic leukemia

Jason Ostergaard; Leslie M Jonart; Maryam Ebadi; Stacia L Koppenhafer; David J Gordon; Peter M Gordon

doi:10.1111/bjh.17610

Back

Preclinical efficacy of prexasertib in acute lymphoblastic leukemia

Journal article

Open access

Peer reviewed

Preclinical efficacy of prexasertib in acute lymphoblastic leukemia

Jason Ostergaard, Leslie M Jonart, Maryam Ebadi, Stacia L Koppenhafer, David J Gordon and Peter M Gordon

British journal of haematology, Vol.194(6), pp.1094-1098

09/2021

DOI: 10.1111/bjh.17610

PMCID: PMC8504167

PMID: 34096630

Files and links (1)

url

https://doi.org/10.1111/bjh.17610View

Published (Version of record) Open Access

Abstract

The addition of molecularly targeted therapies to current chemotherapy regimens may improve acute lymphoblastic leukemia (ALL) outcomes and reduce acute and late toxicities. Checkpoint kinase 1 (CHK1) orchestrates cell cycle checkpoint control in the setting of DNA damage. CHK1 is expressed in both T- and B-ALL and represents a promising therapeutic target. Herein, we show that prexasertib, a targeted CHK1 inhibitor, exhibits significant single-agent efficacy in vivo using ALL patient-derived xenograft (PDX) models and synergizes in vitro with a nucleoside analog. These results support further clinical testing of prexasertib in ALL.

Animals

Cell Line, Tumor

Cell Proliferation - drug effects

Checkpoint Kinase 1 - antagonists & inhibitors

Deoxycytidine - analogs & derivatives

Deoxycytidine - pharmacology

Deoxycytidine - therapeutic use

Drug Synergism

Humans

Mice

Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy

Protein Kinase Inhibitors - pharmacology

Protein Kinase Inhibitors - therapeutic use

Pyrazines - pharmacology

Pyrazines - therapeutic use

Pyrazoles - pharmacology

Pyrazoles - therapeutic use

Details

Title: Subtitle: Preclinical efficacy of prexasertib in acute lymphoblastic leukemia
Creators: Jason Ostergaard - University of Minnesota
Leslie M Jonart - University of Minnesota
Maryam Ebadi - University of Minnesota
Stacia L Koppenhafer - University of Iowa
David J Gordon - University of Iowa
Peter M Gordon - University of Minnesota
Resource Type: Journal article
Publication Details: British journal of haematology, Vol.194(6), pp.1094-1098
DOI: 10.1111/bjh.17610
PMID: 34096630
PMCID: PMC8504167
NLM abbreviation: Br J Haematol
ISSN: 0007-1048
eISSN: 1365-2141
Grant note: R37 CA240846 / NCI NIH HHS R37 CA217910 / NCI NIH HHS
Language: English
Date published: 09/2021
Academic Unit: Stead Family Department of Pediatrics; Hematology/Oncology
Record Identifier: 9984353848202771

Metrics

11 Record Views

3 Times Cited - Web of Science